Treatment for migraine
A first aspect of the invention relates to leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in treating or preventing a migraine, or one or more symptoms associated therewith. A second aspect of the invention relates to a method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method comprising administering to the subject a therapeutically or prophylactically effective amount of leucine, acetyl-leucine, or a pharmaceutically acceptable salt thereof.
1. A method of treating or preventing a migraine, or one or more symptoms associated therewith, in a subject, said method consisting of administering to the subject a therapeutically or prophylactically effective amount of acetyl-leucine, or a pharmaceutically acceptable salt thereof, wherein the migraine is not associated with vertigo or symptoms of vertigo.
2. The method according to claim 1 , wherein the subject is a human.
3. The method of claim 1 , comprising administering to the subject a therapeutically effective amount of acetyl-leucine, or a pharmaceutically acceptable salt thereof.
4. The method according to claim 1 , wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, reduces the frequency of, alleviates, or eliminates one or more symptoms associated with a migraine comprising headache, tiredness, aura, nausea, vomiting, sensitivity to light, sensitivity to sound, sensitivity to smell, sweating, poor concentration, feeling hot, feeling cold, abdominal pain, or diarrhoea.
5. The method according to claim 4 , wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, reduces the frequency of, alleviates, or eliminates a headache.
6. The method according to claim 4 , wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, reduces the frequency of, alleviates or eliminates an aura.
7. The method according to claim 6 , wherein the aura occurs with a headache.
8. The method according to claim 6 , wherein the aura occurs without a headache.
9. The method of claim 6 , wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, reduces the frequency of, alleviates or eliminates one or more symptoms of the aura comprising visual problems or disturbances, numbness or tingling, motor problems, speech difficulties, or loss of consciousness.
10. The method of claim 6 , wherein the acetyl-leucine, or pharmaceutically acceptable salt thereof, treats or prevents pain associated with a migraine.
11. The method of claim 1 , wherein the migraine is a hemiplegic migraine.
12. The method of claim 1 , wherein the migraine is a sporadic hemiplegic migraine.
13. The method of claim 1 , wherein the migraine is a vestibular migraine.
14. The method of claim 1 , wherein the migraine is a basilar-type migraine.
15. The method of claim 1 , wherein the migraine is a retinal migraine.
16. The method of claim 1 , wherein the migraine is chronic migraine.
17. The method of claim 1 , wherein the migraine is episodic migraine.
18. The method of claim 3 , wherein the acetyl-leucine is in racemic form.
19. The method of claim 3 , wherein the acetyl-leucine is in an enantiomeric excess of the L-enantiomer.
20. The method of claim 3 , wherein the acetyl-leucine is administered in a dose of from about 500 mg to about 15 g per day.